Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company also licenses its novel drug delivery technology, ENHANZE. Several companies including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others are using this technology for developing subcutaneous formulation of their currently marketed drugs. It also recognizes revenues from sale of drug products to its collaboration partners for development of drugs using its ENHANZE platform. The company also has one approved product in its portfolio, Hylenex recombinant as an adjuvant to facilitate subcutaneous fluid administration. Although Halozyme has one marketed product, it derives the majority of its revenues from royalties on sales of partnered drugs.
| Revenue (Most Recent Fiscal Year) | $1.02B |
| Net Income (Most Recent Fiscal Year) | $444.09M |
| PE Ratio (Current Year Earnings Estimate) | 11.05 |
| PE Ratio (Trailing 12 Months) | 12.91 |
| PEG Ratio (Long Term Growth Estimate) | 0.38 |
| Price to Sales Ratio (Trailing 12 Months) | 6.22 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 14.02 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 11.76 |
| Pre-Tax Margin (Trailing 12 Months) | 55.79% |
| Net Margin (Trailing 12 Months) | 44.76% |
| Return on Equity (Trailing 12 Months) | 136.91% |
| Return on Assets (Trailing 12 Months) | 26.05% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.39 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.30 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 3.13 |
| Inventory Turnover (Trailing 12 Months) | 1.20 |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.91 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.03 |
| Earnings per Share (Most Recent Fiscal Year) | $3.97 |
| Diluted Earnings per Share (Trailing 12 Months) | $3.76 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 123.22M |
| Free Float | 120.26M |
| Market Capitalization | $6.74B |
| Average Volume (Last 20 Days) | 3.38M |
| Beta (Past 60 Months) | 1.26 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 97.79% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |